Novo Nordisk reported a decline in adjusted earnings per share and revenue for Q1 2026, primarily due to the exclusion of a one-time US 340B benefit. Despite this, the company's GLP-1 franchise, particularly Wegovy, showed strong volume growth. However, ongoing pricing pressures and margin compression in the US market have led to cautious full-year guidance for 2026. The stock trades at a significant discount compared to sector peers, presenting a potential long-term investment opportunity if volume growth and margin stabilization drive earnings recovery beyond 2026.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
